earnings
CR
NASDAQ · CRIS
Curis, Inc.
Healthcare · Biotechnology
$1.13
Up+$0.01 (+0.89%)
Updated Sep 16, 2026, 9:00 AM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 16.68M
- P/E ratio
- -0.55
- Dividend yield
- 0.00%
- 52-week range
- $0.18 – $11.40
- Volume
- 156.75K
- Avg. volume
- 86.2K
Price performance
CRIS price history
1M range · 20 trading sessions · Daily adjusted prices
CRIS closed at $1.13 after 20 trading sessions, down 33.53% for the selected period.
- Last close
- $1.13
- Period change
- -33.53%
- Period low
- $1.12
- Period high
- $1.72
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.12 | $1.21 | $1.08 | $1.13 | 156.75K |
| Sep 14, 2026 | $1.16 | $1.19 | $1.11 | $1.12 | 136.02K |
| Sep 11, 2026 | $1.18 | $1.245 | $1.13 | $1.13 | 131.3K |
| Sep 10, 2026 | $1.21 | $1.2373 | $1.11 | $1.16 | 146.65K |
| Sep 9, 2026 | $1.34 | $1.34 | $1.18 | $1.20 | 188.41K |
| Sep 8, 2026 | $1.32 | $1.35 | $1.26 | $1.27 | 144.68K |
| Sep 4, 2026 | $1.37 | $1.39 | $1.30 | $1.35 | 96.91K |
| Sep 3, 2026 | $1.42 | $1.42 | $1.35 | $1.37 | 126.04K |
| Sep 2, 2026 | $1.46 | $1.4754 | $1.38 | $1.38 | 85.27K |
| Sep 1, 2026 | $1.45 | $1.4717 | $1.40 | $1.42 | 65.42K |
| Aug 31, 2026 | $1.48 | $1.53 | $1.4085 | $1.49 | 35.84K |
| Aug 28, 2026 | $1.51 | $1.58 | $1.45 | $1.49 | 119.83K |
| Aug 27, 2026 | $1.56 | $1.5892 | $1.40 | $1.50 | 288.29K |
| Aug 26, 2026 | $1.59 | $1.6099 | $1.51 | $1.54 | 105.41K |
| Aug 25, 2026 | $1.61 | $1.64 | $1.55 | $1.59 | 142.44K |
| Aug 24, 2026 | $1.60 | $1.65 | $1.5109 | $1.58 | 83.11K |
| Aug 21, 2026 | $1.63 | $1.6595 | $1.50 | $1.58 | 212.51K |
| Aug 20, 2026 | $1.71 | $1.715 | $1.59 | $1.61 | 133.88K |
| Aug 19, 2026 | $1.72 | $1.75 | $1.65 | $1.72 | 196.45K |
| Aug 18, 2026 | $1.83 | $1.93 | $1.68 | $1.70 | 282.12K |
Latest CRIS news
The latest Smart Investors Daily articles mentioning CRIS.
Stock researchCompany · Overview
CRIS research
Overview
Company profile and research snapshot.
Company profile
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 24, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 20, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 10, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.